A Phase 2 Study of TAK-659, an Investigational Reversible Dual SYK/FLT3 Inhibitor, in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

被引：2
|
作者：
Phillips, Tycel J. [1 ]
Salles, Gilles [2 ]
Landsburg, Daniel J. [3 ]
Gritti, Giuseppe [4 ]
Patel, Krish [5 ]
Tilly, Herve [6 ,7 ]
Thieblemont, Catherine [8 ]
Townsend, William [9 ]
Ferrari, Silvia [4 ]
Stumpo, Kate F. [10 ]
Katyayan, Shilpi [10 ,11 ]
Li, Cheryl [10 ]
Miao, Harry [10 ]
Proscurshim, Igor [10 ]
Gopal, Ajay K. [12 ]
机构：
[1] Univ Michigan, Reg Canc Ctr, Ann Arbor, MI 48109 USA
[2] Univ Lyon, Lyon Sud Hosp, Lyon, France
[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA
[4] Osped Papa Giovanni XXIII, Hematol & Bone Marrow Transplant Unit, Bergamo, Italy
[5] Swedish Canc Inst, Ctr Blood Disorders & Stem Cell Transplantat, Seattle, WA USA
[6] Ctr Henri Becquerel, Dept Haematol, Rouen, France
[7] Ctr Henri Becquerel, INSERM 1245, Rouen, France
[8] St Louis Univ Hosp, Div Hematooncol, Paris, France
[9] Univ Coll London Hosp NHS Fdn Trust, Dept Haematol, London, England
[10] Millennium Pharmaceut Inc, Cambridge, MA USA
[11] Cytel Inc, Cambridge, MA USA
[12] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Div Med Oncol,Dept Med, Seattle, WA 98195 USA
来源：
BLOOD | 2019年 / 134卷
关键词：
D O I：
10.1182/blood-2019-125650
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5310
引用
收藏
页数：5
相关论文
共 50 条
  • [21] A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Kambhampati, Swetha
    Kallam, Avyakta
    Borogovac, Azra
    Chen, Lu
    Puverel, Sandrine
    Johnson, Jennifer
    Melgar, Ivana
    Baird, John H.
    Danilov, Alexey
    Godfrey, James
    Khan, Niloufer
    Mei, Matthew
    Phillips, Tycel J. J.
    Siddiqi, Tanya
    Shouse, Geoffrey
    Zain, Jasmine
    Kwak, Larry W.
    Rosen, Steven T.
    Forman, Stephen J.
    Song, Joo Y.
    Herrera, Alex F.
    Budde, Elizabeth
    BLOOD, 2024, 144 : 17421 - 17422
  • [22] Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
    Salles, Gilles
    Gopal, Ajay K.
    Minnema, Monique C.
    Wakamiya, Karen
    Feng, Huaibao
    Schecter, Jordan M.
    Wang, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (05): : 275 - 284
  • [23] Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
    Robertson, Michael J.
    Kahl, Brad S.
    Vose, Julie M.
    de Vos, Sven
    Laughlin, Mary
    Flynn, Patrick J.
    Rowland, Kendrith
    Cruz, Jose C.
    Goldberg, Stuart L.
    Musib, Luna
    Darstein, Christelle
    Enas, Nathan
    Kutok, Jeffery L.
    Aster, Jon C.
    Neuberg, Donna
    Savage, Kerry J.
    LaCasce, Ann
    Thornton, Donald
    Slapak, Christopher A.
    Shipp, Margaret A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (13) : 1741 - 1746
  • [24] Copanlisib in Combination with Nivolumab in Subjects with Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Primary Mediastinal Large B-Cell Lymphoma: A Phase 2 Study
    Bennani, N. Nora
    Nowakowski, Grzegorz
    Rimsza, Lisa M.
    Adjei, Alex A.
    Doyle, Laurence
    Ansell, Stephen M.
    BLOOD, 2019, 134
  • [25] SYK and STAT3 Are Active in Diffuse Large B-Cell Lymphoma: Activity of Cerdulatinib, a Dual SYK/JAK Inhibitor
    Wang, Y. Lynn
    Ma, Jiao
    Xing, Wei
    Lu, Pin
    Dresser, Karen
    Guo, Ailin
    Pandey, Anjali
    Conley, Pamela B.
    Yu, Hongbo
    Coffey, Greg
    BLOOD, 2014, 124 (21)
  • [26] A Phase 2b Study of Selinexor in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)
    Kalakonda, Nagesh
    Cavallo, Federica
    Follows, George
    Goy, Andre
    Vermaat, Joost S. P.
    Casasnovas, Olivier
    Lavee, Orly
    Maerevoet, Marie
    Zijlstra, Josee
    Bakhshi, Sameer
    Bouabdallah, Reda
    Choquet, Sylvain
    Gurion, Ronit
    Hill, Brian
    Jaeger, Ulrich
    Sancho, Juan-Manuel
    Schuster, Michael
    Thieblemont, Catherine
    De la Cruz, Fatima
    Egyed, Miklos
    Mishra, Sourav
    Offner, Fritz
    Vassilakopoulos, Theodoros
    Warzocha, Krzysztof
    McCarthy, Daniel
    Ma, Xiwen
    Corona, Kelly
    Saint-Martin, Jean-Richard
    Joshi, Anita
    Shah, Jatin
    Van den Neste, Eric
    Canales, Miguel
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S248 - S249
  • [27] Multicenter Phase II Study of Bendamustine Plus Rituximab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Ohmachi, Ken
    Niitsu, Nozomi
    Uchida, Toshiki
    Kim, Seok Jin
    Ando, Kiyoshi
    Takahashi, Naoki
    Takahashi, Naoto
    Uike, Naokuni
    Eom, Hyeon Seok
    Chae, Yee Soo
    Terauchi, Takashi
    Tateishi, Ukihide
    Tatsumi, Mitsuaki
    Kim, Won Seog
    Tobinai, Kensei
    Suh, Cheolwon
    Ogura, Michinori
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (17) : 2103 - +
  • [28] A MULTICENTER PHASE II STUDY OF BENDAMUSTINE WITH RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
    Kim, W. S.
    Ando, K.
    Niitsu, N.
    Ogura, M.
    Takahashi, N.
    Uike, N.
    Eom, H. Seok
    Chae, Y. S.
    Tobinai, K.
    Terauchi, T.
    Tateishi, U.
    Tatsumi, M.
    Suh, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 94 - 94
  • [29] A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Collins, Graham P.
    Toby, Eyre A.
    Hatton, Chris S.
    Radford, John
    Linton, Kim M.
    BLOOD, 2014, 124 (21)
  • [30] Phase 2 study of axicabtagene ciloleucel in Japanese patients with relapsed or refractory large B-cell lymphoma
    Kato, Koji
    Makita, Shinichi
    Goto, Hideki
    Kanda, Junya
    Fujii, Nobuharu
    Shimada, Kazuyuki
    Akashi, Koichi
    Izutsu, Koji
    Teshima, Takanori
    Fukuda, Natsuko
    Sumitani, Tokuhito
    Sumi, Hiroyuki
    Shimizu, Shinji
    Kakurai, Yasuyuki
    Yoshikawa, Kenji
    Tobinai, Kensei
    Usui, Noriko
    Hatake, Kiyohiko
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (01) : 213 - 223
12345